Phase4 Ventures

investment firm

About

Phase4 Ventures is a venture capital firm based in London that invests in development stage life science companies in the US.

Details

Industries
Finance,Financial Services,Venture Capital
Founded date
Jan 1, 1999
Operating Status
Active
Investor Type
Venture Capital

Phase4 Ventures is a venture capital firm based in London that invests in development stage life science companies in the US and Europe. Founded in 1999, the team has made close to 30 investments in Life Science companies alongside other top tier venture capital firms in both Europe and the US. The team is complemented by an extensive group of advisors with operating experience at a senior level in pharmaceutical and biotechnology companies. Phase4 Ventures' investments include many of the companies that have provided successful European and US venture exits including Intercell, Pharmion, Targacept and most recently Proteolix.

Phase4 Ventures was spun-out from Nomura in December 2010 following a buy out of the management company by the team and a secondary purchase of a fund by HarbourVest Partners. Phase4 Ventures currently manages funds for both Nomura and HarbourVest.

Phase4 Ventures Limited is a member of the British Private Equity and Venture Capital Association (BVCA) and the European Private Equity and Venture Capital Association (EVCA).

Investments

Number of Investments
Number of Lead Investments
11
6
Phase4 Ventures has made 11 investments. Their most recent investment was on Aug 6, 2009, when Zosano Pharma raised $30M.
Date Company Name
Round Money Raised Industry Lead Investor
Aug 6, 2009 Zosano Pharma
Series B $30M Biopharma
Series B $154M Biotechnology Yes
Sep 8, 2008 Proteolix
Series C $79M Biopharma Yes
Nov 15, 2007 Zosano Pharma
Series A $90M Biopharma
Series Unknown $56M Biotechnology Yes

Exits

Phase4 Ventures has had 6 exits. Phase4 Ventures most notable exits include Nabriva Therapeutics ,   Zosano Pharma

Date Company Name Exit Type Industry
Sep 18, 2015 Nabriva Therapeutics IPO Biotechnology Detail
Jan 27, 2015 Zosano Pharma IPO Biopharma Detail
Jul 26, 2013 OncoMed Pharmaceuticals IPO Biotechnology Detail
Oct 12, 2009 Proteolix M&A Biopharma Detail
Nov 7, 2007 ARYx Therapeutics IPO Biotechnology Detail